Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Eli lilly and company crawled date : 2022 - 04 - 11 save search
Better Together: New Licensing and Collaboration Deals to Watch
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: -2.44%
H: 3.61%
C: 2.68%
collaboration license
Inflammatory Bowel Disease Market Is Anticipated to Progress at a CAGR of 8.0% in the APAC Region for the Study Period of 2018 to 2030, Estimates DelveInsight
Published: 2022-04-11 (Crawled : 16:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 3.07%
H: 0.0%
C: -0.32%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 4.5%
H: 0.0%
C: 0.0%
GLPG | News | $28.78 -2.28% -2.33% 140K
|
Health Technology
|
| O: -1.31%
H: 0.06%
C: -2.47%
disease market
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
Published: 2022-04-11 (Crawled : 14:20) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
disease dermatitis
Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program
Published: 2022-04-11 (Crawled : 13:20) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
antibody program license
Faeth Therapeutics Expands Leadership Team with Thomas Strack as Chief Medical Officer and Virginia Casadas as Head of Clinical Operations
Published: 2022-04-11 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
therapeutics
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
Published: 2022-04-11 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.82%
H: 0.59%
C: -1.88%
ibi322 results antibody phase 1
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
Published: 2022-04-10 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
license
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.